Page 11234..1020..»

Actum Pharma Expands Executive Team to Launch Enhanced Services Program to Support Biopharma Product Commercialization and Market Success

Posted: April 21, 2025 at 2:45 am

BERWYN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- Actum Pharma (Actum), a strategy and operating business partner to global biopharma manufacturers, today announces two executive appointments to launch a new service platform designed to help life science companies fund, develop, manage and market novel, life-changing therapies. The addition of Donovan Quill, chief strategy officer of Life Sciences, and Bob Gilkin, RPh, MBA, chief commercial and growth officer, uniquely position Actum to address the unmet needs of biopharma companies as they work to navigate market challenges, optimize capital, demonstrate capability to investors and achieve early and long-term milestones.

View post:
Actum Pharma Expands Executive Team to Launch Enhanced Services Program to Support Biopharma Product Commercialization and Market Success

Posted in Global News Feed | Comments Off on Actum Pharma Expands Executive Team to Launch Enhanced Services Program to Support Biopharma Product Commercialization and Market Success

BVI Medical Announces Approval of Breakthrough Technology: FDA 510(k) Clearance of its Laser Endoscopy Ophthalmic System: Leos™

Posted: April 21, 2025 at 2:45 am

WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- BVI Medical, a leading global ophthalmic device company dedicated to sitting at the forefront of advancements in eye surgery, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its innovative glaucoma surgical system, Leos™ (Laser Endoscopy Ophthalmic System)

Original post:
BVI Medical Announces Approval of Breakthrough Technology: FDA 510(k) Clearance of its Laser Endoscopy Ophthalmic System: Leos™

Posted in Global News Feed | Comments Off on BVI Medical Announces Approval of Breakthrough Technology: FDA 510(k) Clearance of its Laser Endoscopy Ophthalmic System: Leos™

Best Testosterone Booster Supplements For Muscle Gain & Increase Testosterone For Men Over 40 Or 50 Over The Counter Pills By (Testo Prime)

Posted: April 21, 2025 at 2:44 am

GLASGOW, United Kingdom, April 17, 2025 (GLOBE NEWSWIRE) -- 'Testosterone' does not need any introduction as it is the primary hormone in men, responsible for all masculine features their bodies hold. From growing muscles to developing masculine attributes like facial/body hair, husky voice, and libido to productivity, it has dozens of roles to play. So if there is any factor affecting this hormone, the body is deprived of all these functions, and people start looking for the best testosterone booster supplements to save their health.

Excerpt from:
Best Testosterone Booster Supplements For Muscle Gain & Increase Testosterone For Men Over 40 Or 50 Over The Counter Pills By (Testo Prime)

Posted in Global News Feed | Comments Off on Best Testosterone Booster Supplements For Muscle Gain & Increase Testosterone For Men Over 40 Or 50 Over The Counter Pills By (Testo Prime)

Best Testosterone Boosters for Men Over 40 and 50: TestoPrime Under Review

Posted: April 21, 2025 at 2:44 am

GLASGOW, United Kingdom, April 17, 2025 (GLOBE NEWSWIRE) -- Which is the best testosterone booster for men over 40 and 50? Join us as we figure it out!

Go here to see the original:
Best Testosterone Boosters for Men Over 40 and 50: TestoPrime Under Review

Posted in Global News Feed | Comments Off on Best Testosterone Boosters for Men Over 40 and 50: TestoPrime Under Review

Best Testosterone Booster Supplements Canada: TestoPrime for Males Over 40 and 50 (By TestoPrime CA)

Posted: April 21, 2025 at 2:44 am

GLASGOW, United Kingdom, April 17, 2025 (GLOBE NEWSWIRE) -- Looking for the best testosterone booster Canada has to offer? You're not alone!

Continue reading here:
Best Testosterone Booster Supplements Canada: TestoPrime for Males Over 40 and 50 (By TestoPrime CA)

Posted in Global News Feed | Comments Off on Best Testosterone Booster Supplements Canada: TestoPrime for Males Over 40 and 50 (By TestoPrime CA)

Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility

Posted: April 21, 2025 at 2:44 am

WARREN, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced it has entered into an agreement with CD 8 Technology Services LLC (“CD8”) for the development and/or acquisition of a turn-key facility that is intended to support both in-house pre-clinical research and GMP cell therapy production capabilities.

Read more from the original source:
Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility

Posted in Global News Feed | Comments Off on Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility

NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

Posted: April 21, 2025 at 2:44 am

NAARDEN, the Netherlands and MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the appointment of Adele Gulfo as an independent director to its Board of Directors. Ms. Gulfo is an established pharmaceutical leader with over three decades of experience in the healthcare industry, distinguished by her expertise in global strategy, operations leadership, and the commercialization of multiple blockbuster medicines including LIPITOR® and CRESTOR®.

Go here to read the rest:
NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

Posted in Global News Feed | Comments Off on NewAmsterdam Pharma Appoints Adele Gulfo to its Board of Directors

TELA Bio to Announce First Quarter 2025 Financial Results

Posted: April 21, 2025 at 2:44 am

MALVERN, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that the Company will report first quarter 2025 financial results on Thursday, May 8, 2025. TELA Bio’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.

Visit link:
TELA Bio to Announce First Quarter 2025 Financial Results

Posted in Global News Feed | Comments Off on TELA Bio to Announce First Quarter 2025 Financial Results

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Posted: April 21, 2025 at 2:44 am

WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for autoimmune diseases, today announced that on April 15, 2025 (the “Grant Date”), the Compensation Committee of the Company’s Board of Directors (the “Committee”) granted non-qualified stock options to two newly hired officers of the Company, each as an inducement material to each officer’s entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4).

Read the rest here:
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Posted in Global News Feed | Comments Off on Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

Posted: April 21, 2025 at 2:44 am

Vincerx common stock suspended by Nasdaq inadvertently; will resume trading at the open of business on April 21, 2025

See the original post:
Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

Posted in Global News Feed | Comments Off on Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

Page 11234..1020..»